Quick summary
Adamax is the most potent Semax derivative, combining the N-acetyl Semax backbone with an adamantyl modification that enhances blood-brain barrier penetration, extends half-life, and upregulates BDNF expression. It is a novel research compound with no independent clinical trials published.
Overview
Adamax is a synthetic neuropeptide combining the N-acetyl Semax backbone with an adamantyl modification derived from P21, another BDNF-potentiating nootropic. Developed within the Russian neuropeptide research tradition, Adamax is considered the most potent Semax derivative. The adamantyl (adamantane) group enhances lipophilicity, protects the peptide from enzymatic degradation, extends its half-life, and facilitates blood-brain barrier penetration.
Mechanism of action
Adamax crosses the blood-brain barrier through enhanced lipophilicity conferred by the adamantyl group, which also protects the peptide from peripheral peptidase degradation. Once in the CNS, Adamax upregulates brain-derived neurotrophic factor (BDNF) expression and enhances the sensitivity of TrkB receptors in the hippocampus — the primary receptor for BDNF signaling. It also modulates dopamine, norepinephrine, and serotonin neurotransmitter systems. The result is enhanced neuroplasticity and improved signal efficiency in circuits underlying working memory, attention, and executive function.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| cognitive enhancement (research / anecdotal) | oral | 100–300 mcg | once daily | Anecdotal protocols suggest starting at 100 mcg/day and titrating up. Nasal spray and IM routes are also used based on Semax-derived convention. |
| cognitive enhancement (intramuscular, research) | intramuscular | 100–200 mcg | once daily | IM may improve bioavailability vs oral. All dosing protocols are user-derived, not from clinical evidence. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Adamax has been commercially available for roughly two years as of 2026. No independent peer-reviewed clinical trials have been published. All available benefit data are anecdotal reports from users describing improvements in focus, memory consolidation, and complex task performance. Preclinical data on parent compounds Semax and P21 provide mechanistic plausibility. Because Adamax is a novel research compound, safety data, dose-response curves, and long-term effects are uncharacterized.[1][2][3][4]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Adamax for synergistic effects.
Legal status
Not approved by FDA or any major regulatory agency. Sold as research chemical in the US and internationally. Not a controlled substance. No established human dosing guidelines from regulatory bodies.
Sourcing & access
Research compound
Adamax is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
Adamax is a synthetic neuropeptide that combines the N-acetyl Semax backbone with an adamantyl modification derived from the nootropic P21. Developed within the Russian neuropeptide research tradition and commercially available for roughly two years as of 2026, it is considered the most potent Semax derivative, though no independent peer-reviewed clinical trials have been published to confirm that claim.
The adamantyl group increases lipophilicity, facilitating blood-brain barrier penetration, and protects the peptide from peripheral peptidase degradation for an extended half-life. In the CNS, Adamax upregulates BDNF expression, enhances TrkB receptor sensitivity in the hippocampus, and modulates dopamine, norepinephrine, and serotonin systems to improve working memory, attention, and executive function.
Safety is not formally characterized because no independent peer-reviewed clinical trials have been published and Adamax has only been commercially available for roughly two years. Anecdotal side effects reported by users include irritability, sleep disruption at higher doses, headache, and rare anxiety. It is not approved by the FDA or any major regulatory agency, and long-term effects and dose-response curves remain uncharacterized.
Anecdotal protocols suggest 100 to 300 mcg orally once daily or 100 to 200 mcg intramuscularly once daily, with users typically starting at the low end and titrating upward. All dosing is user-derived from Semax-family convention and is not supported by clinical trial evidence. Nasal spray dosing mirrors the oral range. No regulatory agency has published human dosing guidelines.
Research references
- Neuropeptide Y and peptide YY: a peptide alliance in the gut-brain axisPubMed
- Neuropeptide Y modulates energy homeostasis and hypothalamic signalingPubMed
- Neuropeptide Y receptors: novel targets in obesity and metabolic diseasePubMed
- NPY and energy balance regulation: hypothalamic circuit controlPubMed